EBIO News Alert Eleven Biotherapeutics Inc. (EBIO) 11.92 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Eleven Biotherapeutics Inc. (EBIO) 11.92 $EBIO

Eleven Biotherapeutics to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Wed Nov 26, 7:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will present a company overview at the Oppenheimer 25th Annual Healthcare Conference in New York on Thursday, December 11, 2014 at 10:55 a.m. ET.
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics expects USD20m from private placement
M2 - Wed Nov 26, 6:44AM CST
Biopharmaceutical company Eleven Biotherapeutics (NasdaqGM:EBIO) disclosed on Tuesday the planned sale of USD20m of its common stock and warrants to a select group of investors.
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics Announces Additional Financing of $20 Million
Business Wire - Tue Nov 25, 7:05AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it has entered into a securities purchase agreement for the sale of $20 million of Eleven Biotherapeutics common stock and warrants in a private placement financing with a select group of investors.
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics revenues down 17% in Q3
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 12:13PM CST

EBIO: 11.92 (+0.07)

Eleven Biotherapeutics' (EBIO) CEO Abbie Celniker on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:51AM CST

EBIO: 11.92 (+0.07)

Eleven Biotherapeutics misses by $0.22, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:44AM CST

EBIO: 11.92 (+0.07)

Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 13, 6:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the third quarter ended September 30, 2014 and recent business highlights.
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics to Report Third Quarter 2014 Financial Results on November 13, 2014
Business Wire - Tue Nov 04, 7:30AM CST
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report third quarter 2014 financial results on Thursday, November 13, 2014. Eleven's management team will host a conference call and audio webcast at 8:30 a.m. EST, on Thursday, November 13, 2014 to discuss the quarterly results and recent business developments.
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of EBI-005 in Patients with Dry Eye Disease
Business Wire - Mon Nov 03, 7:30AM CST
Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease. EBI-005, a topical, novel interleukin-1 (IL-1) receptor blocker, is Eleven's lead drug candidate in development for the treatment of moderate to severe dry eye disease and allergic conjunctivitis.
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics Appoints Wendy L. Dixon, PhD to Board of Directors
Business Wire - Thu Oct 23, 7:30AM CDT
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the appointment of industry veteran Wendy L. Dixon, PhD, former Chief Marketing Officer and President of Global Marketing for Bristol Myers Squibb, to the company's Board of Directors.
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005
Business Wire - Tue Oct 07, 7:30AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the issuance of U.S. Patent No. 8,853,150 entitled "Chimeric Il-1 Receptor Type I Agonists and Antagonists." This patent covers the composition-of-matter of Eleven's lead product candidate, EBI-005, a topically-administered interleukin-1 (IL-1) receptor blocker, certain other compositions that are IL-1 receptor antagonists, and related methods for treating ocular surface inflammatory diseases, such as dry eye disease and allergic conjunctivitis. Designed, engineered and generated using Eleven's AMP-Rx platform, EBI-005 is being developed as a topical protein therapeutic for ocular diseases. Eleven recently reported top-line results of a Phase 2 study of EBI-005 in patients with moderate to severe allergic conjunctivitis and is currently evaluating EBI-005 in a pivotal Phase 3 clinical study in patients with dry eye disease, with top-line data expected in early 2015.
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis
Business Wire - Thu Oct 02, 5:00AM CDT
--- Study Does Not Meet Primary Endpoint Using Environmental Exposure Chamber Model -
EBIO: 11.92 (+0.07)

How Eleven Biotherapeutics (EBIO) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:51AM CDT
Eleven Biotherapeutics might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics to Participate in Upcoming Investor Conferences in September
Business Wire - Thu Aug 28, 3:01PM CDT
Eleven Biotherapeutics (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences in September:
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 13, 6:30AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported business highlights and financial results for the second quarter ended June 30, 2014.
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics to Report Second Quarter 2014 Financial Results on August 13, 2014
Business Wire - Fri Aug 01, 7:30AM CDT
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report second quarter 2014 financial results on Wednesday, August 13, 2014. Eleven's management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time on Wednesday, August 13, 2014 to discuss the quarterly results and recent business developments.
EBIO: 11.92 (+0.07)

Eleven Biotherapeutics to Present at Wedbush 2014 Life Sciences Management Access Conference
Business Wire - Tue Jul 29, 7:30AM CDT
Eleven Biotherapeutics (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will present a company overview at the Wedbush 2014 Life Sciences Management Access Conference in New York on Tuesday, August 12, 2014 at 2:30 p.m. ET.
EBIO: 11.92 (+0.07)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 41

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 147

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 69

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 70

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 134

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 84

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading

Top 5 Most Recently Viewed Articles

Calumet Sets 2025 Plans for Investor Engagement Events

Updated Category News Views 381

Calumet Announces Participation in Upcoming Investor Conferences Calumet, Inc. (NASDAQ: CLMT) is gearing up to make an important presence at two significant investor conferences scheduled for January 2025. The event will offer Calumet a platform to connect with investors and discuss the company's innovative strategies. Goldman Sachs Energy Conference The first conference...

Continue Reading
PACS Group Investors Face Class Action for Alleged Fraud

Updated Category News Views 336

PACS Group Investors Face Class Action for Alleged Fraud In recent developments, a significant class action lawsuit has been initiated against PACS Group, Inc., a recognized leader in the skilled nursing facility sector. The lawsuit, spearheaded by a prestigious law firm, is rooted in serious allegations of securities fraud involving the company and several of its senior...

Continue Reading
Discover the Magic: MINISO Unveils Harry Potter Collection

Updated Category News Views 710

Introducing a Magical Collection from MINISO MINISO, a renowned lifestyle brand celebrated for its affordable quality products, has launched an enchanting array of over 800 Harry Potter-inspired items. This exciting collection will be available in MINISO stores globally, captivating fans of the beloved franchise with affordable yet stylish merchandise that embodies the...

Continue Reading
Westwood Launches Enhanced Income Opportunity ETF for Growth

Updated Category News Views 95

Westwood Launches Enhanced Income Opportunity ETF Westwood Holdings Group, recognized as a leading boutique asset manager, is delighted to announce the creation of the Westwood Enhanced Income Opportunity ETF, also referred to as YLDW. This innovative investment option is a fresh addition to the company’s Enhanced Income Series™ ETFs, which has significantly expanded...

Continue Reading
Upcoming Earnings Announcement: Canadian Pacific Kansas City

Updated Category News Views 161

Canadian Pacific Kansas City to Announce Q2 Earnings Canadian Pacific Kansas City (TSX: CP) has announced its plans to release its financial and operational results for the second quarter of 2025 after market closure. This highly anticipated announcement will take place, giving stakeholders insight into the company's performance and strategic direction. Conference Call...

Continue Reading